Affiliation:
1. Faculty of Pharma Sciences, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
Funder
Ministry of Education, Culture, Sports, Science and Technology
Japan Society for the Promotion of Science
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Reference20 articles.
1. Chapter 6 Advances in Vasopressin Receptor Agonists and Antagonists
2. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents
3. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1 H -1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V 2 receptor antagonist
4. Orally Active, Nonpeptide Vasopressin V2 Receptor Antagonists: A Novel Series of 1-[4-(Benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and Related Compounds
5. Tolvaptan (SAMSCA/JINARC) was approved first as the drug for ADPKD in Japan in 2014, followed by the approval in Canada, Europe, and Korea in 2015.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献